Analysis of Cetuximab resistance mechanism in oral cancer and Development of a novel treatment by combining immunotherapy

2017 Fiscal Year Final Research Report

• Project/Area Number: 16K20592
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Surgical dentistry
• Research Institution: Kumamoto University
• Principal Investigator: Nagata Masashi 熊本大学, 医学部附属病院, 非常勤診療医師 (10635791)
• Project Period (FY): 2016-04-01 – 2018-03-31
• Keywords: 分子標的薬 / 抗がん剤耐性 / EGFR / ADCC活性

Outline of Final Research Achievements

In recent years, reduction of therapeutic effect due to acquisition resistance in molecular targeted drugs has become a problem. We succeeded in establishing Cetuximab resistant cell line in oral squamous cell carcinoma. We recognized cells with high expression of target EGFR and downstream signal phosphorylated Akt showed high sensitivity, suggesting a causal relationship between Cetuximab sensitivity and PI3K / Akt pathway . In addition, since it is suggested that ADCC activity by NK cells and cytotoxicity by other immune cells act as important therapeutic effect factors for molecular targeted drugs, changes in immune cells were confirmed using blood samples, but there was no association with the effect of Cetuximab.

Free Research Field

抗がん剤耐性